Veeva Systems (NYSE:VEEV) Price Target Raised to $300.00

Veeva Systems (NYSE:VEEV) had its target price upped by Oppenheimer from $225.00 to $300.00 in a report published on Monday,Benzinga reports. They currently have an outperform rating on the technology company’s stock.

Other equities analysts have also recently issued research reports about the company. Zacks Research cut Veeva Systems from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. BNP Paribas Exane reiterated an “outperform” rating and issued a $285.00 target price on shares of Veeva Systems in a research note on Thursday, June 4th. Citigroup lifted their target price on Veeva Systems from $176.00 to $190.00 and gave the stock a “neutral” rating in a research report on Thursday, June 4th. UBS Group lowered their target price on shares of Veeva Systems from $220.00 to $190.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Finally, Robert W. Baird upped their price target on shares of Veeva Systems from $250.00 to $260.00 and gave the stock an “outperform” rating in a report on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $253.75.

Veeva Systems Price Performance

Veeva Systems stock opened at $251.01 on Monday. The firm has a market capitalization of $40.77 billion, a P/E ratio of 44.74, a price-to-earnings-growth ratio of 1.04 and a beta of 0.92. Veeva Systems has a 1-year low of $148.05 and a 1-year high of $310.50. The company’s 50-day moving average is $194.64 and its 200 day moving average is $181.16.

Veeva Systems (NYSE:VEEV) last announced its earnings results on Wednesday, June 3rd. The technology company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.10. The business had revenue of $882.95 million during the quarter, compared to analyst estimates of $857.73 million. Veeva Systems had a return on equity of 13.72% and a net margin of 28.37%.The company’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.97 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. Research analysts anticipate that Veeva Systems will post 6.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Thomas D. Schwenger sold 36,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $250.23, for a total value of $9,008,280.00. Following the completion of the sale, the insider directly owned 19,449 shares of the company’s stock, valued at $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Veeva Systems

Large investors have recently modified their holdings of the business. SHP Wealth Management bought a new position in shares of Veeva Systems during the fourth quarter valued at approximately $26,000. Activest Wealth Management lifted its holdings in Veeva Systems by 3,175.0% during the fourth quarter. Activest Wealth Management now owns 131 shares of the technology company’s stock worth $29,000 after buying an additional 127 shares during the period. Arlington Trust Co LLC purchased a new stake in Veeva Systems during the second quarter worth $29,000. Field & Main Bank bought a new stake in Veeva Systems during the 2nd quarter valued at $29,000. Finally, MV Capital Management Inc. bought a new stake in Veeva Systems during the 4th quarter valued at $30,000. Institutional investors own 88.20% of the company’s stock.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Higher analyst targets support the stock: Barclays’ target implies further upside, and Stifel Nicolaus is also forecasting strong appreciation. The consensus rating remains “Moderate Buy,” with institutional ownership at approximately 88%. Barclays raises Veeva Systems price target Stifel Nicolaus forecasts appreciation
• Positive Sentiment: Upcoming earnings are a potential catalyst: Veeva is expected to report quarterly results on Wednesday. Its prior quarter beat estimates, delivering $2.24 in EPS versus a $2.14 consensus and $882.95 million in revenue versus an $857.73 million estimate. Veeva Systems expected earnings release
• Neutral Sentiment: Analyst views remain mixed: Several firms maintain bullish ratings, but earlier target reductions from Canaccord Genuity, BMO Capital Markets and Goldman Sachs indicate concerns about valuation and growth. The average target is near the current trading range, limiting the immediate upside implied by the broader consensus. Wall Street analysts on Veeva Systems
• Negative Sentiment: Growth concerns and insider selling remain risks: Veeva has underperformed the broader market amid softer demand and competition. In addition, insider Thomas Schwenger sold $9.0 million of shares under a pre-arranged Rule 10b5-1 plan, reducing his holdings by nearly 65%. Veeva Systems insider sale

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.